RxDoctor Payments Data

George Miller, MD

Cardiovascular Disease · Sugar Land, TXNPI 1760443790

Payments from drug & device makers

$167,586in general payments, 2019–2025

Across 80 payments — averaging $2094.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$143K
  • Shire North American Group Inc$24K
  • Pfizer$30

What the payments were for

  • Consulting fees$167,486100%
  • Travel & lodging$700%
  • Food & beverage$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$167,586 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$3,597
Medicare patients
17
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl32$7,279
Potassium Chloride13$223
Lisinopril15$89
Furosemide16$87
Methylprednisolone11$71
Dexamethasone19$62
Alprazolam14$44

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →